The Need for Beneficence and Prudence in Clinical Innovation with Autologous Stem Cells

Perspectives in Biology and Medicine 61 (1):90-105 (2018)
  Copy   BIBTEX

Abstract

In recent years, there has been a rapid growth in the use of autologous stem cell-based interventions to treat a wide range of medical conditions, including those for which there is limited evidence of safety and efficacy. One justification for this growth in the use of unproven interventions is that clinicians should be free to innovate, as long as consumers are adequately informed about risks and benefits. In this essay, we systematically refute the strong claim that consumer and clinician autonomy provide sufficient justification for clinical innovation with autologous stem cells. While we do not deny the importance of consumer and clinician autonomy, we argue that equal consideration needs to be given...

Other Versions

No versions found

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 103,449

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Ownership issues in autologous stem cell therapies.Patrick Foong Chee Kuen - 2019 - Eubios Journal of Asian and International Bioethics 29 (6):186-190.

Analytics

Added to PP
2018-05-22

Downloads
22 (#1,015,764)

6 months
1 (#1,572,794)

Historical graph of downloads
How can I increase my downloads?

References found in this work

No references found.

Add more references